Serum salusin-alpha, is decreased in essential hypertension and acute coronary syndrome. The study is aimed to explore whether serum salusin-alpha is associated with atherosclerosis and left ventricular (LV) diastolic dysfunction in essential hypertension. Echocardiography, carotid ultrasonography, brachial-ankle pulse wave velocity (BaPWV) and serum salusin-alpha levels were determined in 60 hypertensive patients (29 with and 31 without carotid plaque) and 30 normotensive controls. Hypertensive patients with plaque, compared with those without plaque or the controls, had the lowest values of salusin-alpha. Then the hypertensive patients were divided into left ventricular hypertrophy (LVH) and non-LVH groups according to the echocardiography. Similarly, hypertensive patients with LVH showed the lowest serum salusinalpha levels. In all subjects, serum salusin-alpha levels were negatively correlated with carotid mean-intimamedia thickness (IMT), BaPWV, left ventricle mass index (LVMI) and E/E 0 (r ¼ À0.488, Po0.001; r ¼ À0.381, Po0.001; r ¼ À0.294, P ¼ 0.006; r ¼ À0.303, P ¼ 0.005; respectively). Serum salusin-alpha levels were independent predictors of BaPWV, carotid strain, carotid distensibility, mean-IMT, LVMI and E 0 /A 0 (b ¼ À0.399, 0.283, 0.237, À0.346, À0.306, 0.469; P ¼ 0.002, 0.031, 0.016, 0.005, 0.012 and 0.001, respectively) in multiple linear regression models. These results suggest that serum salusin-alpha may be associated with atherosclerosis and LV diastolic dysfunction in essential hypertension.
Introduction
Essential hypertension is a common risk factor for cardiovascular disease. Identification of patients at high risk by detection of preclinical disease, when target-organ damage may be in an early and potentially reversible stage, has been emphasized in recent years. Atherosclerosis, which is often observed in early stage of essential hypertension, involves two important changes: thickening and stiffening of the arterial wall. Carotid ultrasonography, which is a well-accepted, non-invasive method of assessing early changes in vascular structure, can provide information about the presence of intima media thickness (IMT), plaque and arterial remodeling. Aortic PWV is the current 'gold-standard' measure of arterial stiffness and associated with end-organ alterations, such as increased ventricular stress and arterial intima-media thickening.
1 PWV is also an independent predictor of cardiovascular mortality. 2 Meanwhile, carotid atherosclerosis is associated with left ventricular (LV) hypertrophy and LV diastolic dysfunction. 3, 4 LV diastolic dysfunction is common in hypertensive patients and it strongly predicts cardiovascular morbidity and overall mortality in hypertensive patients. 5, 6 Salusins are newly identified bioactive peptides discovered by bioinformatics analysis of a fulllength complememtary DNA library. 7 Shichiri et al. 7 recently characterized two related peptides of 28 and 20 amino acids designated salusin-alpha and salusin-beta, respectively. It was reported that development of atherosclerosis may be accelerated by salusin-beta and suppressed by salusin-alpha via acyl-CoA cholesterol acyltransferase-1(ACAT-1) regulation in acute coronary syndrome. 8 Previous study 9 has shown that serum salusin-alpha levels are decreased and correlated negatively with maximum IMT in essential hypertensive patients.
Thus, we speculated salusin-alpha may be involved in essential hypertension. However, the correlations between serum salusin-alpha and the severity of target organ damages are still unclear. This study is aimed to investigate the relationships of salusinalpha with these well-established parameters of atherosclerosis and LV diastolic dysfunction.
Methods
Study population This is a cross-sectional design. A total of 60 consecutive hypertensive patients referred between November 2009 and May 2010 to our hospital for cardiovascular risk assessment were eligible. They were divided into two groups, with (plaque group, n ¼ 29) or without (non-plaque group, n ¼ 31) carotid plaque according to carotid ultrasound. Hypertension was defined as a systolic blood pressure (BP) of X140 mm Hg and/or a diastolic BP of X90 mm Hg on repeated measurements. Exclusion criteria were: clinical or laboratory evidence of heart failure, coronary heart disease, cerebrovascular disease, valvular defects and secondary causes of hypertension. The control group consisted of 30 healthy subjects without a history of cardiac disease or systemic hypertension. The control had normal findings on physical examination, Holter monitor and echocardiography. The study protocol was approved by the ethics committee of our institution. All of the subjects enrolled in this study were Chinese, and all of the subjects gave informed consent to participate in this study.
Baseline clinical characteristics
Height and body weight were measured, and body mass index was calculated. Anti-hypertensive treatment was recorded. BP was measured with an appropriate arm cuff and a mercury column sphygmomanometer on the left arm after a resting period of X10 min in the supine position. After fasting overnight, venous blood sampling from all of the subjects was performed. The following parameters were also determined: total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, FBG, urea nitrogen, creatinine and uric acid.
Serum salusin-alpha levels detected by enzyme-linked immunosorbent assay Serum salusin-alpha levels were determined by the enzyme-linked immuno-sorbent assay kit (Bachem, Bubendorf, Switzerland). The standard curve was made with concentrations of 5, 2.5, 1.25, 0.625, 0.313, 0.156, 0.078, 0.039 and 0.02 ng ml À1 . Samples were prepared by diluting 50 ml of serum with 25 ml of blocking buffer and incubated at 37 1C for 1 h. Then 25 ml of Bt-tracer was added into each well except the blank and incubated at 37 1C for 2 h. After the incubation, the plates were washed with a washing buffer (phosphate-buffered saline containing Tween-20, 0.05%, pH 7.5) for a total of five times. In the following step, the plates were incubated with the 100 ml per well of the streptavidin-horseradish peroxidase-labeled C-terminal antibody (1:30 diluted in antibody solution) at room temperature for 30 min. In the next steps, the plates were incubated with the 100 ml per well of 3,3 0 ,5,5 0 -tetramethylbenzidine solution under light-protected conditions at room temperature for 30 min. Finally, the plates were applied with the 100 ml per well of HCL (2N) to stop the reaction. The absorbance values were measured at 450 nm.
Carotid ultrasound investigation
To evaluate the progression of carotid atherosclerosis, high-resolution B-mode ultrasonography using of 7.5 MHz probe (Vivid 7; GE Vingemed Ultrasound, Horten, Norway) was performed. One experienced technician operated the machine with no previous information about the study. All ultrasound images were obtained with the patient in the supine position with the neck mildly extended and rotated to the contralateral side, and measurements of IMT and plaque score were performed on the frozen frame, perpendicular to the vascular walls, by scanning bilateral common and internal carotid arteries at the time of examination. In each subject, the maximum and mean IMT values were obtained by IMT measurements in six sites of the far walls in bilateral carotid arteries excluding the plaque. The upper normal limit of IMT was 1.0 mm, and the lesions with a focal IMTX1.1 mm were defined as plaques. 10 The plaque score was calculated by summing all plaque thickness measurements in both carotid arteries. The severity of plaque score was graded as follows: none, 0; mild, 1.1-5; moderate, 5.1-10; and severe, X10.1.
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Carotid artery elastic parameters Internal diameter measurements were made by continuous tracing of the intima-lumen interfaces of the near and far walls. According to the Atherosclerosis Risk in Communities study protocol and Tomiyama's studies, [11] [12] [13] carotid strain was assessed as DD Â 100/Dd, where DD and Dd represent pulsatile distension and end-diastolic diameter, respectively. Carotid artery distensibility (DC) and stiffness (SC) coefficients were calculated according to the following formulas: DC ¼ (Ds 2 ÀDd 2 ) Â 100/ (Dd 2 Â DP) and SC ¼ DP Â Dd/DD where DP and Ds represent carotid artery pulse pressure and endsystolic diameter, respectively. Two-dimensional, M-mode, pulsed doppler echocardiography Echocardiography was performed with the patients positioned in the left lateral decubitus position Salusin-alpha, atherosclerosis and diastolic dysfunction Y Ti et al using VIVID 7 system (Vivid 7, GE Systems) with a 2.5 MHz transducer. Two-dimensional guided M-mode echocardiograms were obtained just below the mitral valve leaflets at the chordal level. All echocardiograms were recorded and stored in a hard disk and were analyzed later. Septal and posterior wall thickness and left ventricle chamber dimensions were measured according to the American Society of Echocardiography guidelines. The left ventricle mass index (LVMI) was determined by the ASE-recommended formula: 'LVMI (g m
À13.6)/ body surface area'. The presence of LVH was established by echocardiography and defined as LVMI 4125 g m À2 for men and 4110 g m À2 for women. 14 According to the LVMI, we also divided the hypertensive patients into LVH group and non-LVH group. Fractional shortening (FS%) was calculated as: FS% ¼ 100 Â (LVIDdÀLVIDs)/LVIDd where LVID was LV internal dimension; d was end-diastole; s was endsystole. Midwall fractional shortening was calculated as
). LVPWs and IVSs were end-systolic posterior wall and interseptum thickness.
Tissue doppler
Tissue Doppler imaging (TDI) of the mitral annulus was obtained from the apical four-chamber view. A 1.5-mm sample volume was placed sequentially at the lateral and medial mitral annulus. Analysis was performed for the peak velocities during sustained systole (S 0 ), early (E 0 ) and late diastolic velocity (A 0 ). All Doppler signals were recorded with a chart recorder set at 100 mm s
À1
. The average of three endexpiratory cycles was used.
Brachial-ankle pulse wave velocity (BaPWV) measurement After the subject had rested in a supine position for at least 10 min, BaPWV was measured using an automated device (Omron-Colin, Tokyo, Japan). This device can measure the electrocardiogram, phonocardiogram, ankle brachial pressure index and PWV as well as the BP. BaPWV was calculated as the distance traveled by the arterial pulse wave (cm) divided by the time(s) delay between the two arterial points, thus expressed as centimeters per second. Ankle brachial pressure index was the ratio of ankle systolic BP to brachial systolic BP. The average of bilateral BaPWV and ankle brachial pressure index was used for analysis. The use of this device has been validated previously. 15 
Statistical analysis

Results
The clinical characteristics of the subjects in all groups are listed in Table 1 . The systolic, diastolic BP, pulse pressure, low-density lipoprotein cholesterol levels and uric acid were significantly greater in both plaque and non-plaque groups than in normotensive controls, and were more prominent in the plaque group. However, serum salusin-alpha levels were significantly decreased in hypertensive patients than in normotensive controls, and were more severe in plaque group (Table 1) .
According to the carotid ultrasound and PWV investigation, the mean-IMT, max-IMT and carotid stiffness coefficient were significantly greater in both plaque and non-plaque groups than in control, and were more prominent in the plaque group. The values of carotid strain and distensibility coefficient were lower in hypertensive group when compared with the control group, and were more severe in the plaque group (Table 1) . The BaPWV was significantly greater in both plaque and non-plaque groups compared with controls, with the significantly highest levels observed in the plaque group (1702.20±256.96, 1537.06±307.16 and 1253.50± 97.15 cm s À1 , respectively). There was no significant difference in ankle brachial index (Table 1) .
According to echocardiography results, IVSd, LVPWd, LVMI and E/E 0 were significantly greater in hypertensive patients than the controls, and were more prominent in the LVH group. The values of Midwall fractional shortening (%), E/A and E 0 /A 0 were lowest in the LVH group. Similarly, there is an observed decrease of serum salusin-alpha levels in LVH group compared with the non-LVH group and the controls ( Table 2) . In all subjects, after controlling for age, gender, body mass index, systolic BP, diastolic BP, total cholesterol, triglycerides, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol, serum salusin-alpha levels showed significant correlations with carotid mean-IMT, BaPWV, LVMI, E 0 /A 0 and E/E 0 (r ¼ À0.488, Po0.001; r ¼ À0.381, Po0.001; r ¼ À0.294, P ¼ 0.006; r ¼ 0.519, Po0.001; r ¼ À0.303, P ¼ 0.005; respectively) ( Table 3) ; moreover, there was a significant association between serum salusin-alpha levels and plaque scores (r ¼ À0.495, P ¼ 0.005) in plaque group (Table 3) .
Multiple linear regression analysis revealed that salusin-alpha had significant independent associations with BaPWV, carotid strain, carotid distensibility, carotid mean-IMT, LVMI and E 0 /A 
Discussion
In the present study, salusin-alpha levels are decreased and seem to be significantly correlated with preclinical markers of atherosclerosis and LV diastolic dysfunction in essential hypertension. These findings suggest a link between low salusinalpha levels and the presence of atherosclerosis and LV diastolic dysfunction.
Salusin-alpha is associated with preclinical atherosclerotic markers in essential hypertension
Aortic stiffness has independent predictive value for total and cardiovascular mortality in patients with essential hypertension. 16, 17 Aortic (or carotid-femoral) PWV is higher in patients with atherosclerotic cardiovascular disease 18 and correlates with IMT of carotid artery. In our study, we detected BaPWV, which has been shown to be closely correlated with the aortic PWV. 19 As we known, advancing age and BP are the main factors leading to arterial stiffening. Nevertheless, in the present study, we have identified significant negative correlations between salusin-alpha levels and BaPWV after proper adjustment for age and BP values. Additionally, salusin-alpha had significant independent correlations with carotid strain and carotid distensibility, which are other main parameters of describing mechanical properties of arteries. Our current study is the first to report associations between serum salusin-alpha levels and arterial elastic parameters. Taken together, decreased salusin-alpha may influence the functional changes of the arteries in early stage hypertension. 
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Carotid ultrasound investigation may be the best method of detecting initial generalized atherosclerosis and assessing the subsequent risk of vascular events. 20, 21 In our study, hypertensive subjects were divided into plaque group and non-plaque group according to carotid plaque. There was a significant negative correlation between serum salusin-alpha levels and the carotid mean-IMT in all subjects, which was in accordance with previous study. 9 Meanwhile, serum salusin-alpha levels showed significant correlation with the plaque scores. So we speculated that serum salusin-alpha levels might be associated with both initial and advanced atherosclerosis. Shichiri et al. 8 have shown that salusin-alpha suppresses foam cell formation in human monocyte-derived macrophages in acute coronary syndrome, contributing to its anti-atherosclerotic effect. Therefore, it is possible that decreased salusin-alpha may have a causal role in the process of atherosclerotic plaque formation. Collectively, salusin-alpha may be involved in different stages of hypertension, from initiation to progression. Further studies are required to determine the association between serum salusin-alpha levels and the end-stage hypertension with clinical cardiovascular events.
Salusin-alpha is associated with LV diastolic dysfunction in essential hypertension
The presence of LV diastolic dysfunction, in particular when measured with tissue Doppler, is not only related to a greater risk of the development of heart failure, but is also associated with a poor prognosis. 22 Previous studies have shown that subjects with a severe plaque burden had reduced LV systolic and diastolic function compared with Salusin-alpha, atherosclerosis and diastolic dysfunction Y Ti et al controls. 23, 24 E/E 0 has become a reliable variable for diastolic dysfunction and future cardiac morbidity and mortality. 25 The association of arterial stiffness with LV structure and LV function, particularly diastolic dysfunction, has been studied in patients with hypertension. 26 Given the associations between the atherosclerosis and LV diastolic dysfunction, we also detected the correlation between salusin-alpha and LV diastolic dysfunction. Our results showed that serum salusin-alpha levels were significantly lower in LVH group compared with the control and non-LVH groups. Meanwhile, serum salusin-alpha levels showed significant correlations with LVMI, E 0 /A 0 and E/E 0 after controlling for age, gender, body mass index, systolic BP, diastolic BP, total cholesterol, triglycerides, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol. Moreover, serum salusin-alpha levels were independent predictors of LVMI and E 0 /A 0 . These results suggest that serum salusin-alpha may be associated with LV diastolic dysfunction in essential hypertension.
Salusin-alpha may be involved in the pathogenesis of essential hypertension Serum salusin-alpha levels were significantly decreased in essential hypertension; however, there was no direct correlation between serum salusinalpha levels and BP. These observations suggest that serum salusin-alpha may not have effective role through the direct control of physiological BP changes. It has been reported that systemic administration of salusins to rats is associated with mild hypotension and bradycardia. 7 Salusin-beta, which is theoretically synthesized concomitantly with salusin-alpha, causes profound hypotension without exerting an appreciable vasodilatory effect. The hypotensive effect of salusins is achieved partly through activation of the parasympathetic nervous system. 7 As we know, elevated sympathetic nervous system activation has been shown in hypertension. So we speculate that the decreased salusin-alpha levels may lose the function to activate the parasympathetic nervous system, which resulted in shifting the autonomic balance toward the sympathetic dominant state. Chronic higher sympathetic responsiveness may cause the occurrence of essential hypertension. So decreased serum salusin-alpha levels may be involved in the pathogenesis of essential hypertension, but the mechanism and the physiological significance underlying these changes need to be further investigated.
A potential limitation in the present study is that our findings presented are based on cross-sectional design, prospective studies should provide further insights into the possible cause-effect relationships between preclinical markers and salusin-alpha. The differences of salusin-alpha among the three groups expressed small effects, there may be many other factors influencing the associations between preclinical markers and salusin-alpha. Additionally, in the present study, we only measured Ba PWV. Although the BaPWV has been shown to be closely correlated with the aortic PWV, it also includes peripheral muscular arterial stiffness. 19 BaPWV may be a less ideal measure of large artery stiffness than central PWV. In the future study, aortic (or carotidfemoral) PWV should be measured.
Conclusions
In conclusion, serum salusin-alpha may be associated with atherosclerosis and LV diastolic dysfunction in essential hypertension.
